Results 191 to 200 of about 599,269 (342)

Studies in Pharmacokinetics and Tolerance of Substances Temporarily Retained in the Liver by Microsphere Embolization

, 1978
B Lindell, Karl‐Fredrik Aronsen, B Nosslin, U. Rothman   +3 more
openalex   +2 more sources

Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer

Advanced Science, EarlyView.
This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan, Kun Shao, Roopa Hebbandi Nanjundappa, Daniel‐Jiajun Yu, Marianne Stanford, Huile Gao, Channakeshava Sokke Umeshappa   +6 more
wiley   +1 more source

Pharmacokinetic and pharmacodynamic characterization of remimazolam in older Japanese adults who underwent general anesthesia at early stage of infusion. [PDF]

Sci Rep
Ueshima S, Nagahara S, Nakaya K, Kawamura M, Hira D, Matsuura Y, Toyama H, Kawamae K, Kakumoto M.   +8 more
europepmc   +1 more source

Pharmacokinetics and Safety of Cefamandole in Infants and Children [PDF]

, 1978
Chia Tien Chang, Abdul J. Khan, Melanie M. Agbayani, Ramesh Jhaveri, Irfan Amin, H.E. Evans   +5 more
openalex   +1 more source

Advanced Pharmaceutical Nanotechnologies Applied for Chinese Herbal Medicines

Advanced Science, EarlyView.
This review offers a comprehensive overview of pharmaceutical nanotechnology strategies to address limitations associated with the complex material basis and relative mild therapeutic efficacy of Chinese herbal medicines, and summarizes the advantages of these strategies.
Jiameng Li, Ya‐Li Zhang, Tong Jin, Zhaokui Jin, Mengliang Zhu, Guangchao Qing, Jinchao Zhang, Zhisen Wang, Yan Mu, Jin Li, Qian Hua, Xing‐Jie Liang   +11 more
wiley   +1 more source

An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy

Advanced Science, EarlyView.
This study develops a dimeric T cell receptor engager protein specific for tumor KRAS‐G12V mutation. The engager proteins are capable of mediating the formation of synapse between T cell and tumor cell and demonstrate substantial tumor suppression efficacy.
Keke Ma, Jie Wang, Min Jiang, Juanhua He, Fangyang Li, Dan Lu, Chao Su, Yan Chai, Wenjing Jin, Yu Chen, Catherine W.H. Zhang, Xiaopeng Ma, Hui Tan, George F. Gao, Shuguang Tan   +14 more
wiley   +1 more source

ADME Properties in Drug Delivery. [PDF]

Pharmaceutics
Scotti L, Scotti MT.
europepmc   +1 more source

Nanoparticle‐Mediated CXCL12–CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma

Advanced Science, EarlyView.
Molecular mechanism study of self‐assembled M2pep‐Cs NPs/Plerixafor nanoparticles in targeting MΦ reprogramming by regulating the CXCL12–CXCR4 signaling pathway to enhance immune recognition and clearance of GC (Created by BioRender). Abstract Gastric carcinoma (GC) remains a major global health challenge, requiring novel therapeutic approaches.
Qianqian Cao, Xiaolei Cheng, Rongbin Lv, Dianshui Sun, Jihua Wang, Runjia Fu, Rumei Gong, Yueying Xiao, Qin Liu, Xiaomei Li   +9 more
wiley   +1 more source

Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?

CPT: Pharmacometrics & Systems Pharmacology, 2023
Shinji Yamazaki, Raymond Evers, Loeckie De Zwart   +2 more
doaj   +1 more source

Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies. [PDF]

Clin Transl Sci
Iwai M, Heo N, Hashimoto K, Guro S, Moy S, Spence A, Wojtkowski T, Benner L, Helmick M, Zhu T, Ferslew BC.   +10 more
europepmc   +1 more source